TNI6 low-BMD sensitivity
0.67 proportion
- EndpointLow-BMD classification sensitivity
- PopulationTNI6 validation dataset
- Tested versionRho
Authorized purpose: Rho analyzes standard frontal radiographs opportunistically to identify patients aged 50 years and older who may have low bone mineral density and to prompt clinical bone-health assessment.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Rho analyzes standard frontal radiographs opportunistically to identify patients aged 50 years and older who may have low bone mineral density and to prompt clinical bone-health assessment.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a retrospective, multi-center study comparing Rho with DXA (low BMD: T-Score <-1.0 at a femoral neck or L1-L4) on 3729 TNI6, 522 OneMedNet and 591 Osteoarthritis Initiative cases. Sensitivity was 0.67 (0.66-0.69), 0.45 (0.41-0.50) and 0.36 (0.31-0.41), and specificity 0.90 (0.88-0.92), 0.93 (0.90-0.96) and 0.94 (0.92-0.96), for TNI, OMN and OAI; sensitivity was comparatively low, while specificity and AUC goals were met in all three datasets. Results are as reported in the FDA submission, not independent validation.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Packet wording: "Clinical performance of the device was provided in the form of a retrospective, multi-center study to compare sensitivity and specificity of the device with the gold standard" … "Ground truth low BMD is defmed as at least one of the femoral necks or L1-L4 vertebrae having a T-Score <-1.0 when assessed by DXA.". Read from the exact FDA decision document on 2026-11-14.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Packet wording: "Clinical performance of the device was provided in the form of a retrospective, multi-center study to compare sensitivity and specificity of the device with the gold standard" … "Ground truth low BMD is defmed as at least one of the femoral necks or L1-L4 vertebrae having a T-Score <-1.0 when assessed by DXA.". Read from the exact FDA decision document on 2026-11-14.
Packet wording: "n Sensitivity Specificity AUC group All data split by dataset TNI 3729 0.67 (0.66-0.69) 0.90 (0.88-0.92) 0.88 (0.88-0.90) OMN 513 0.45 (0.41-0.50) 0.93 (0.90-0.96) 0.85 (0.82-0.88) OAI 591 0.36 (0.31-0.41) 0.94 (0.92-0.96) 0.82 (0.79-0.85)" … "Ground truth Low BMD was defined by DXA (at least one of the femoral neck or L1-4 having a T-score <-1).". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Packet wording: "n Sensitivity Specificity AUC group All data split by dataset TNI 3729 0.67 (0.66-0.69) 0.90 (0.88-0.92) 0.88 (0.88-0.90) OMN 513 0.45 (0.41-0.50) 0.93 (0.90-0.96) 0.85 (0.82-0.88) OAI 591 0.36 (0.31-0.41) 0.94 (0.92-0.96) 0.82 (0.79-0.85)" … "Ground truth Low BMD was defined by DXA (at least one of the femoral neck or L1-4 having a T-score <-1).". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
0.67 proportion
0.9 proportion
0.45 proportion
0.36 proportion
DEN230023
FDA tables include TNI6 n=3,729, OMN n=513, and OAI n=591; the De Novo record is the source anchor and linked FDA review contains detailed tables.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
No exact-product reimbursement determination identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesThis public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Standard frontal DICOM radiographs plus patient age and sex.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-04 · FDA De Novo record DEN230023: Rho
Source context, not route validation: The FDA De Novo materials describe DICOM radiograph input, PACS interface, and positive-result delivery to PACS or a browser.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 · FDA De Novo record DEN230023: Rho
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Source context, not route validation: A positive or negative low-BMD report; positive reports are sent to PACS or a browser, while negative reports do not generate an output.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-04 · FDA De Novo record DEN230023: Rho
Unresolved route: A positive or negative low-BMD report; positive reports are sent to PACS or a browser, while negative reports do not generate an output.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-04 · FDA De Novo record DEN230023: Rho
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to DEN230023.
exact submission · checked 2026-09-04The exact public deployment boundary is incomplete; confirm hosting, data flow, availability, upgrades, security, service, and downtime locally.
exact submission · checked 2026-09-04The FDA De Novo materials describe DICOM radiograph input, PACS interface, and positive-result delivery to PACS or a browser.
exact submission · checked 2026-09-04Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for DEN230023.
exact submission · checked 2026-09-04Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.
product family · checked 2026-09-04Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.
exact submission · checked 2026-09-04Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
No evidence was promoted. Every record concerns Rho biology or an unrelated clinical intervention and does not identify the 16 Bit Rho device or DEN230023. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda denovo record, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price or commercial contract for the exact submission and version was identified.
No exact-product payer coverage or reimbursement determination was identified in reviewed public material.
The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.
Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
7 sources - 3 history items
Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: coverage, codingContext
Scope: recallDiscovery, nativeSubmissionMatching
Regulatory record
De Novo
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Alpha Intelligence Manifolds, Inc.
Authorized purpose: Opportunistic review of frontal lumbar-spine or KUB radiographs in adults aged 50 years and older to flag possible low bone mineral density at L1-L4 for clinician follow-up; a negative result does not rule out low BMD.
AZmed
Authorized purpose: Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.
Velmeni, Inc.
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Qure.Ai Technologies
Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history